Mitomycin C in recurrent or extensive ocular surface neoplasia

Role of mitomycin C (MMC) is searched in recurrent cases with squamus cell carcinoma (SCC), conjunctival -corneal intraepithelial neoplasia (CCIN) or in advanced cases of ocular surface neoplasm in whom, surgical excision was impossible due to extensive involvement of ocular surface. Seventeen cases of SCC. CCIN or PAM(primary acquired melanosis) with atypia were selected. They received three cycles of MMC (0.04%) eye drop four times a day for one week. Participants were followed for 4-36 months. There were 7 females and 10 males.7 patients (4 1.1 %) developed one time recurrence after first course of treatment but during follow up, only 3 of them (17.6%) needed su rggical management while 4 others responded to another course of treatment. Six out of 17 patients (35.2%) had another systemic disease and received either chemotherapy or radiation before.We conclude that even though the trend for use of chemotherapy as a sole drug or in adjunct with surger in the treatment of ocular surface neoplasia is rising, surgical c y resection still remains the first line procedure in the manaaernent of limited forms of CCIN or aggressive and invasive SCC while they are concise. Only in recurrent cases or extensive involvement of ocular surface, prescription of MMC may be reasonable.